Opinions
Jim Cramer - Mad Money
Ocugen
OCGN-Q
COMMENT
Apr 28, 2021
Stock price when the opinion was issued
You might be interested:
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free
OCGN operates as a small-cap biotech company that focuses on developing novel genes, cell therapies, and vaccines. OCGN generates very limited revenue. OCGN is still burning cash ($62M in the last 12 months), and issuing shares to support its research. The balance sheet has $18M in cash, and, given the burn rate, OCGN should be expected to issue more shares soon. The stock has done very well on early clinical success. But trials are still Phase I/II, and trials are actually quite small. Its focus is on gene therapy with retinal (eye) applications. In such scenarios, stocks are often binary: soaring on good results, crashing on bad results. Insiders own about 2% and have been recent sellers. We do not know this one well enough to recommend but risks need to be considered extremely high.
Unlock Premium - Try 5i Free